Engineered immune cells take on Hard-to-Treat ovarian cancer in first human test
NCT ID NCT06305299
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This early-phase study tests whether a new treatment using a patient's own modified immune cells (called CAR T cells) is safe for women with ovarian cancer that came back after standard platinum-based chemotherapy. The cells are designed to target a protein called B7-H3 found on cancer cells and include a safety switch to stop them if needed. About 27 participants will receive the cells after a short chemotherapy course to help them work better. The main goal is to find the safest dose and watch for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.